Ligand Pharmaceuticals | LGND - Операционные расходы





Операционные расходы Изменить Дата
Agenus USD -199.08M 22.15M 2026-06
Amgen USD 5.69B 6B 2026-09
Anika Therapeutics USD 137.28M 3.38M 2026-06
Arrowhead Research USD 245.35M 30.35M 2026-06
Baxter International USD 6.5B 3.82B 2026-09
Bristol-Myers Squibb USD 23.4B 1.08B 2026-09
Eli Lilly USD 10.52B 496M 2026-06
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Enviri Corporation USD 233.18M 357.11M 2026-03
Gilead Sciences USD 13.04B 9.09B 2026-09
GlaxoSmithKline GBP 6.03B 227M 2026-09
Glaxosmithkline GBP 6.76B 1.42B 2026-09
Heron Therapeutics USD 40.55M 1.46M 2025-12
Insmed USD 606.26M 79.46M 2026-09
Intrexon USD 61.56M 26.1M 2024-06
Ionis Pharmaceuticals USD 373M 2.76M 2026-09
Karyopharm Therapeutics USD 61.83M 9.9M 2026-03
Ligand Pharmaceuticals USD 94.5M 39.4M 2026-09
MacroGenics USD 25.15M 17.72M 2026-09
Merck USD 10.75B 5.02B 2026-09
Pacira USD 1.18B 995.96M 2026-09
Pfizer USD 89B 3.81B 2026-09
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Veracyte USD 133.73M 7.37M 2026-09